Original InvestigationDose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
Under a Creative Commons license
open access
Central Illustration
Key Words
biomarker
cardiac remodeling
dose
heart failure
sacubitril/valsartan
Abbreviations and Acronyms
ACE
angiotensin-converting enzyme
ARB
angiotensin receptor blocker
ARNI
angiotensin receptor neprilysin inhibitor
GDMT
guideline-directed medical therapy
HFrEF
heart failure with reduced ejection fraction
hs-cTnT
high sensitivity cardiac troponin T
KCCQ-23
Kansas City Cardiomyopathy Questionnaire-23
LVEF
left ventricular ejection fraction
NT-proBNP
N-terminal pro–B-type natriuretic peptide
Sac/Val
sacubitril/valsartan
Cited by (0)
Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on www.jacc.org/journal/jacc.
Joseph G. Rogers, MD, served as Guest Associate Editor for this paper. Christie M. Ballantyne, MD, and Athena Poppas, MD, served as Guest Editors-in-Chief for this paper.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.